Literature DB >> 12847181

Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study.

S J Tabrizi1, A M Blamire, D N Manners, B Rajagopalan, P Styles, A H V Schapira, T T Warner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12847181     DOI： 10.1212/01.wnl.0000070186.97463.a7

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  14 in total

Review 1.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

2.  Creatine supplementation lowers brain glutamate levels in Huntington's disease.

Authors:  Andreas Bender; Dorothee P Auer; Thomas Merl; Ralf Reilmann; Phillip Saemann; Alexander Yassouridis; Julia Bender; Adolf Weindl; Matthias Dose; Thomas Gasser; Thomas Klopstock
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

3.  A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis.

Authors:  Nazem Atassi; Eva-Maria Ratai; David J Greenblatt; Darlene Pulley; Yanli Zhao; Jeffery Bombardier; Stuart Wallace; Joanna Eckenrode; Merit Cudkowicz; Allitia Dibernardo
Journal:  Amyotroph Lateral Scler       Date:  2010-08-11

4.  Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.

Authors:  Michael J Mihm; Deborah M Amann; Brandon L Schanbacher; Ruth A Altschuld; John Anthony Bauer; Kari R Hoyt
Journal:  Neurobiol Dis       Date:  2006-11-27       Impact factor: 5.996

Review 5.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 6.  Beyond muscles: The untapped potential of creatine.

Authors:  Lisa A Riesberg; Stephanie A Weed; Thomas L McDonald; Joan M Eckerson; Kristen M Drescher
Journal:  Int Immunopharmacol       Date:  2016-01-08       Impact factor: 4.932

Review 7.  Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Miles R Bryan; Aaron B Bowman
Journal:  Adv Neurobiol       Date:  2017

8.  Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism.

Authors:  Simon J A van den Bogaard; Eve M Dumas; Wouter M Teeuwisse; Hermien E Kan; Andrew Webb; Raymund A C Roos; Jeroen van der Grond
Journal:  J Neurol       Date:  2011-05-26       Impact factor: 4.849

9.  Nucleic Acid-Based Therapy Approaches for Huntington's Disease.

Authors:  Tatyana Vagner; Deborah Young; Alexandre Mouravlev
Journal:  Neurol Res Int       Date:  2012-01-11

Review 10.  Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.

Authors:  Dénes Zádori; Péter Klivényi; Imola Plangár; József Toldi; László Vécsei
Journal:  J Cell Mol Med       Date:  2011-04       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.